Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Antidiabetics, statins and the risk of amyotrophic lateral sclerosis

European Journal of Neurology(2020)10.1111/ene.14190Source: DataRank Database

Antidiabetics, statins and the risk of amyotrophic lateral sclerosis is a research paper published in European Journal of Neurology (2020). On theSindex it has a DataRank of 0. It has been cited 39 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access39 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 1.84)OA: hybridTopics (45)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Freya Kamel ORCID,Rino Bellocco ORCID,Lars‐Olof Ronnevi,C. Almqvist,Henrik Larsson ORCID

Live enrichment

PubMed:32097525 PMC:PMC10957794 OpenAlex:https://openalex.org/W3008362605

Forskningsrådet om Hälsa, Arbetsliv och Välfärd

Grant: 2013‐00782

Vetenskapsrådet

Grant: 2019‐01088

Intramural NIH HHS

Grant: Z01 ES049005

Swedish Research Council for Health, Working Life and Welfare

Grant: unidentified

unidentified

Karolinska Institutet

EU Joint Programme – Neurodegenerative Disease Research

FWCI

1.84

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ene.14190

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ene.14190

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fene.14190

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.14190

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1111/ene.14190

Fields of Study

Amyotrophic Lateral Sclerosis ResearchParkinson's Disease and Spinal DisordersGenetic Neurodegenerative Diseases03 medical and health sciences0302 clinical medicineAmyotrophic Lateral SclerosisCase-Control StudiesDiabetes Mellitus, Type 2FemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsRisk FactorsSweden

MeSH Terms

Amyotrophic Lateral SclerosisDiabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsRisk FactorsSwedenCase-Control StudiesHydroxymethylglutaryl-CoA Reductase Inhibitors

Keywords

MedicineAmyotrophic lateral sclerosisPhysical medicine and rehabilitationNeuroscienceInternal medicineDiseaseDiabetesrisk factorsAntidiabeticsstatinsSwedenClinical Neurologyamyotrophic lateral sclerosis; antidiabetics; diabetes; risk factors; statins;ArticleEU Joint Programme – Neurodegenerative Disease ResearchNeurologyDiabetes Mellitus, Type 2Case-Control StudiesHumansHypoglycemic AgentsFemaleHydroxymethylglutaryl-CoA Reductase Inhibitors

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being